Cognition Therapeutics Inc (CGTX)

02:40 AM

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Buy” from Analysts - Defense World

02:40 AM

Apr 25, 2025

Cognition Therapeutics Inc [CGTX] Shares Fall Approximately -76.27% Over the Year - knoxdaily.com

Apr 25, 2025

Apr 25, 2025

Cognition Therapeutics Inc (CGTX) Stock: Navigating a Year of Volatility - investchronicle.com

Apr 25, 2025

Apr 09, 2025

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2024 Earnings Call Transcript - MSN

Apr 09, 2025

Apr 08, 2025

Tscan Therapeutics Inc (TCRX) deserves deeper analysis - uspostnews.com

Apr 08, 2025

Apr 08, 2025

2025 Is Shaping Up To Be A Big Year For This Drug Maker Working To Cure Dementia - Benzinga

Apr 08, 2025

Apr 03, 2025

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Rating of “Buy” by Analysts - Defense World

Apr 03, 2025

Apr 01, 2025

Cognition Therapeutics reports promising Alzheimer’s study results By Investing.com - Investing.com South Africa

Apr 01, 2025

Apr 01, 2025

Cognition Therapeutics reports promising Alzheimer’s study results - Investing.com

Apr 01, 2025

Apr 01, 2025

Cognition Therapeutics Presents Results at AD/PD 2025 - GlobeNewswire

Apr 01, 2025

Apr 01, 2025

Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes - TradingView

Apr 01, 2025

Apr 01, 2025

Breakthrough: Cognition's Alzheimer's Drug Reduces Multiple Disease Markers in Phase 2 Trial - Stock Titan

Apr 01, 2025

Mar 28, 2025

Equities Analysts Set Expectations for CGTX FY2025 Earnings - Defense World

Mar 28, 2025

Mar 27, 2025

Contrasting Alpha Cognition (NASDAQ:ACOG) & Cognition Therapeutics (NASDAQ:CGTX) - Defense World

Mar 27, 2025

Mar 27, 2025

HC Wainwright Has Bearish Estimate for CGTX Q1 Earnings - Defense World

Mar 27, 2025

Mar 26, 2025

Dementia Associated With Alzheimer’s Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

Mar 26, 2025

Mar 26, 2025

What is HC Wainwright’s Forecast for CGTX Q1 Earnings? - Defense World

Mar 26, 2025

Mar 25, 2025

Cognition Therapeutics to Report Biomarker Results from - GlobeNewswire

Mar 25, 2025

Mar 25, 2025

Cognition Therapeutics to present Alzheimer’s study results By Investing.com - Investing.com South Africa

Mar 25, 2025

Mar 25, 2025

Agitation in Alzheimer's Disease Market: Analysis - openPR.com

Mar 25, 2025

Mar 25, 2025

Cognition to Reveal Biomarker Findings Next Week - Baystreet.ca

Mar 25, 2025

Mar 25, 2025

Cognition Therapeutics to present Alzheimer’s study results - Investing.com India

Mar 25, 2025

Mar 25, 2025

Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025 - The Manila Times

Mar 25, 2025

Mar 25, 2025

Cognition Therapeutics to Present Phase 2 SHINE Study Biomarker Results for Zervimesine at AD/PD 2025 Conference - Nasdaq

Mar 25, 2025

Mar 25, 2025

Game-Changing Alzheimer's Treatment: New Phase 2 Data Reveals Multiple Positive Biomarkers - Stock Titan

Mar 25, 2025

Mar 25, 2025

Cognition Therapeutics (NASDAQ:CGTX) Price Target Cut to $5.00 by Analysts at HC Wainwright - Defense World

Mar 25, 2025

Mar 24, 2025

Cognition Therapeutics stock price target cut to $5 at H.C. Wainwright - Investing.com Canada

Mar 24, 2025

Mar 23, 2025

Cognition Therapeutics Earnings Call: Progress Amid Challenges - MSN

Mar 23, 2025

Mar 23, 2025

Chardan Capital Has Lowered Expectations for Cognition Therapeutics (NASDAQ:CGTX) Stock Price - Defense World

Mar 23, 2025

Mar 21, 2025

Brookline Capital lifts Cognition Therapeutics stock to $7 target By Investing.com - Investing.com Canada

Mar 21, 2025

Mar 21, 2025

Cognition Therapeutics Inc (CGTX) Q4 2024 Earnings Call Highlights: Strategic Focus on ... By GuruFocus - Investing.com Canada

Mar 21, 2025

Mar 21, 2025

New Horizons in Lewy Body Dementia Market Exploring Future - openPR.com

Mar 21, 2025

Mar 21, 2025

Cognition Therapeutics: Navigating the Complexities of Alzheimer's and DLB Trials - AInvest

Mar 21, 2025

Mar 21, 2025

Cognition Therapeutics Advances Alzheimer’s and DLB Trials - TipRanks

Mar 21, 2025

Mar 20, 2025

Earnings call transcript: Cognition Therapeutics Q4 2024 sees $34M net loss - Investing.com Australia

Mar 20, 2025

Mar 20, 2025

Cognition Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 20, 2025

Mar 20, 2025

COGNITION THERAPEUTICS Earnings Results: $CGTX Reports Quarterly Earnings - Nasdaq

Mar 20, 2025

Mar 20, 2025

COGNITION THERAPEUTICS INC SEC 10-K Report - TradingView

Mar 20, 2025

Mar 20, 2025

Cognition Therapeutics, Inc. Reports Positive Phase 2 Results for Zervimesine in Dementia with Lewy Bodies and Alzheimer's Disease, Plans Advancement to Late-Stage Trials - Nasdaq

Mar 20, 2025

Mar 20, 2025

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update - GlobeNewswire

Mar 20, 2025

Mar 19, 2025

Lewy Body Dementia Market to Show Remarkable Growth Trends from - openPR

Mar 19, 2025

Mar 18, 2025

Alzheimer's disease Clinical and Non-Clinical Studies, Key - openPR

Mar 18, 2025

Mar 18, 2025

Cognition Therapeutics (CGTX) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 18, 2025

Mar 13, 2025

Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results - The Manila Times

Mar 13, 2025

Mar 13, 2025

Cognition Therapeutics Q4 Earnings: Key Date Revealed for Crucial Neurodegenerative Treatment Updates - StockTitan

Mar 13, 2025

Mar 13, 2025

Cognition Therapeutics at Life Sciences Forum: Progress in Alzheimer’s and Lewy Body Dementia - Investing.com UK

Mar 13, 2025

Mar 13, 2025

Cognition Therapeutics shifts to Nasdaq Capital Market By Investing.com - Investing.com India

Mar 13, 2025

Mar 12, 2025

Cognition Therapeutics, Inc. Transitions to Nasdaq Capital Market Following Compliance Notification - Nasdaq

Mar 12, 2025